May 2015 in “Cancer research” This study found that persistent significant alopecia was a common side effect following FEC-docetaxel chemotherapy, with a 33.4% global incidence, highlighting the need for awareness and potential preventative measures like cooling caps during treatment.
68 citations
,
May 2012 in “Annals of Oncology” This study reports that permanent and severe alopecia is a newly identified complication of the FEC 100–docetaxel regimen used for adjuvant breast cancer treatment.
23 citations
,
July 2018 in “Journal of Cosmetic Dermatology” This study describes a distinct pattern of trichoscopic features associated with chemotherapy-induced alopecia and how these features evolve through different phases of chemotherapy treatment.
March 2010 in “Ejc Supplements” This study highlights a paradox where valproic acid, known for causing hair loss, may also promote hair growth when applied topically.
This study aims to describe the trichoscopic pattern of chemotherapy-induced alopecia and its changes during different phases of chemotherapy.